Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease with a versatile
and complicated profile, being the fourth most common single cause of death worldwide …

Background COPD is the fourth leading cause of death in the world. It is a common,
progressive, treatable and preventable disease. The exacerbation of COPD is associated …

Prescription of mucoactive drugs for chronic obstructive pulmonary disease (COPD) is
increasing. This development in clinical practice arises, at least in part, from a growing …

Background: Carbocysteine is a muco-active drug with free radical scavenging and anti-
inflammatory properties. It is actually approved for clinical use as adjunctive therapy of …

OBJECTIVE: COPD is one of the major causes of morbidity and mortality worldwide and
represents one of the most important issues for public health. Frequent exacerbations …

Abstract Background Chronic Obstructive Pulmonary Disease (COPD) is a chronic and
progressive lung disease characterized by irreversible airflow obstruction, airway …

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality
worldwide. Oxidative stress is an important mechanism in the pathogenesis of this disease …

Background Chronic obstructive pulmonary disease (COPD) is characterised by airflow
limitation, and has many components including mucus hypersecretion, oxidative stress, and …

It has been shown that mucus hypersecretion is associated with greater susceptibility for
chronic obstructive pulmonary disease (COPD), excess forced expiratory volume in 1 s …

Aim To investigate the effects of carbocisteine treatment in the reduction of frequency of
productive cough episodes, preventing disease progression and improving the quality of life …